期刊： UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2023; 41 (1)
Purpose: Urachal carcinoma (UC) is a rare genitourinary cancer with an insidious onset, high risk of recurrence, and a poor prognosis. Surgical resect......
期刊： UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2023; 41 (1)
Background: Nephrometry scores aid in clinical decision-making, yet evidence is scarce regarding their impact on cumulative morbid-ity following parti......
期刊： UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2023; 41 (6)
Introduction: To measure the level of endothelial cell-specific molecule-1 (ESM-1) expression among the Renal Cell Cancer (RCC) variants using by immu......
期刊： UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2023; 41 (6)
Purpose: To develop predictive models based on the integration of radiomics with the Vesical Imaging-Reporting and Data System (VIRADS) for determinin......
期刊： UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2023; 41 (8)
Background: Cisplatin-based chemotherapy (ChT) is the preferred perioperative treatment in muscle-invasive urothelial carcinoma of the urinary bladder......
期刊： UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2023; 41 (10)
Purpose: Urothelial carcinomas (UCs) are often characterized by frequent recurrences after surgery, making UC one of the costliest cancers. Chromosoma......
期刊： UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2023; 41 (12)
Aim: Gamma-delta-T cells (y8T) have potential antitumor roles and have recently been applied in adoptive immunotherapy. In the present study, we focus......
期刊： UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2023; 41 (3)
This systematic review and meta-analysis aimed to evaluate the postoperative renal and cardiovascular outcomes of partial nephrectomy (PN) versus radi......
期刊： UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2023; 41 (5)
Introduction: The path to approval of novel therapeutics for patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) requires demons......
期刊： UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2023; 41 (8)
Introduction: While Prostate Imaging Reporting and Data System (PI-RADS) 4 and 5 lesions usually justify prostate biopsy (PBx), the management of a PI......
期刊： UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2023; 41 (10)
Background: Muscle-invasive bladder cancer (MIBC) patients have benefitted greatly from immune checkpoint blockade (ICB) therapy. However, there is a ......
期刊： UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2023; 41 (2)
Objectives: To externally validate the previously published Mayo clinic model for the prediction of early (<30 days) postoperative renal failure, w......
期刊： UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2023; 41 (3)
Purpose: We sought to quantify mCRPC patient treatment patterns and survival across multiple lines of therapy after prior androgenreceptor-axis-target......
期刊： UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2023; 41 (5)
Background & Objective: Asymptomatic microhematuria (aMh) remains a diagnostic challenge in urological practice: while aMh is a risk factor of uro......
期刊： UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2023; 41 (7)
Purpose: To explore the role of circadian clock gene NR1D1 (REV-erb alpha) in bladder cancer (BC). Methods: Firstly, the association of NR1D1 level wi......
